STOCK TITAN

[Form 4] KORU Medical Systems, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

KORU Medical Systems (KRMD) reported an insider equity transaction. On 10/16/2025, the President and CEO was issued 29,463 shares of common stock at $4.08 per share under her employment agreement as the stock portion of the 2024 annual bonus (30% stock, 70% cash).

Following the transaction, she beneficially owned 1,052,626 shares. This includes 200,000 restricted stock awards that vest based on a market capitalization schedule prior to 3/15/27, and 600,000 restricted stock awards that vest based on net sales growth targets for fiscal years ended 12/31/22 through 12/31/25.

KORU Medical Systems (KRMD) ha riferito una transazione azionaria di insider. Il 16/10/2025, la Presidente e CEO ha ricevuto 29,463 azioni ordinarie al prezzo di 4,08 USD per azione nell'ambito del suo accordo di lavoro come parte azionaria del bonus annuale 2024 (30% azioni, 70% in contanti).

Dopo la transazione, lei possedeva beneficiamente 1.052.626 azioni. Ciò include 200.000 premi di azioni restritte che si vestono secondo un calendario di capitalizzazione di mercato prima del 15/03/27, e 600.000 premi di azioni restritte che si vestono secondo obiettivi di crescita delle vendite nette per gli esercizi chiusi al 31/12/22 fino al 31/12/25.

KORU Medical Systems (KRMD) informó de una transacción de insider de acciones. El 16/10/2025, la Presidenta y CEO recibió 29.463 acciones comunes a un precio de 4,08 USD por acción según su acuerdo de empleo, como la parte en acciones del bono anual 2024 (30% acciones, 70% en efectivo).

Tras la operación, ella poseía beneficiariamente 1.052.626 acciones. Esto incluye 200.000 premios de acciones restringidas que se consolidan de acuerdo con un calendario de capitalización de mercado antes del 15/03/27, y 600.000 premios de acciones restringidas que se consolidan según metas de crecimiento de ventas netas para los ejercicios fiscales terminados el 31/12/22 hasta el 31/12/25.

KORU Medical Systems (KRMD)는 내부자 주식 거래를 보고했습니다. 2025년 10월 16일, 사장 겸 CEO는 고용 계약에 따라 2024년 연간 보너스의 주식 부분(주식 30%, 현금 70%)으로 주당 4.08달러의 일반주 29,463주를 받았습니다.

거래 후 그녀는 유익하게 1,052,626주를 소유하게 되었습니다. 여기에는 200,000주 제한 주식 보상이 포함되며 이는 2027년 3월 15일 이전의 시장자본화 일정에 따라 귀속되고, 600,000주 제한 주식 보상은 2022년 12월 31일부터 2025년 12월 31일까지의 순매출 성장 목표를 기반으로 귀속됩니다.

KORU Medical Systems (KRMD) a publié une opération sur actions par initié. Le 16/10/2025, la Présidente et PDG a reçu 29 463 actions ordinaires à 4,08 USD par action dans le cadre de son accord d'emploi, en tant que la partie actions du bonus annuel 2024 (30% actions, 70% en espèces).

Après la transaction, elle détenait bénéficiairement 1 052 626 actions. Cela comprend 200 000 attributions d'actions restreintes qui vestent selon un calendrier de capitalisation boursière avant le 15/03/27, et 600 000 attributions d'actions restreintes qui vestent selon des objectifs de croissance du chiffre d'affaires net pour les exercices clos au 31/12/22 au 31/12/25.

KORU Medical Systems (KRMD) meldete eine Insider-Eigenkapitaltransaktion. Am 16.10.2025 erhielt die Präsidentin und CEO im Rahmen ihrer Beschäftigungsvereinbarung als Aktienanteil des Jahresbonus 2024 (30% Aktien, 70% Bargeld) 29.463 Stammaktien zu 4,08 USD pro Aktie.

Nach der Transaktion besaß sie beneficial 1.052.626 Aktien. Dazu gehören 200.000 Restricted-Stock Awards, die gemäß einem Kalender zur Marktkapitalisierung vor dem 15.03.2027 vesten, sowie 600.000 Restricted-Stock Awards, die basierend auf Zielen zum Nettoumsatzwachstum für die Geschäftsjahre endend am 31.12.22 bis zum 31.12.25 vesten.

KORU Medical Systems (KRMD) أبلغت عن صفقة أسهم داخلية. في 16/10/2025، تم منح الرئيسة والمديرة التنفيذية اتفاق توظيفها كجزء من مكافأة 2024 السنوية بالأسهم بمعدل 29,463 سهمًا عاديًا بسعر 4.08 دولار للسهم لكل سهم.

بعد الصفقة، امتلكت بشكل فعّال 1,052,626 سهمًا. ويشمل ذلك 200,000 جائزة أسهم مقيدة تكتسب وفقًا لجدول رسملة السوق قبل 15/03/27، و600,000 جائزة أسهم مقيدة تستحق وفقًا لأهداف نمو صافي المبيعات للفترة المالية المنتهية في 31/12/22 حتى 31/12/25.

KORU Medical Systems (KRMD) 报告了一项内幕股权交易。2025/10/16,董事长兼首席执行官在其雇佣协议下,作为2024年度奖金的股票部分(30%股票,70%现金)获授29,463股普通股,价格为每股4.08美元。

交易后,她受益所有权持有1,052,626股。其中包括<200,000股受限股票奖励,根据市值资本化日程在<2027/3/15前归属,以及<600,000股受限股票奖励,基于截至2022/12/31至2025/12/31的净销售额增长目标归属。

Positive
  • None.
Negative
  • None.

KORU Medical Systems (KRMD) ha riferito una transazione azionaria di insider. Il 16/10/2025, la Presidente e CEO ha ricevuto 29,463 azioni ordinarie al prezzo di 4,08 USD per azione nell'ambito del suo accordo di lavoro come parte azionaria del bonus annuale 2024 (30% azioni, 70% in contanti).

Dopo la transazione, lei possedeva beneficiamente 1.052.626 azioni. Ciò include 200.000 premi di azioni restritte che si vestono secondo un calendario di capitalizzazione di mercato prima del 15/03/27, e 600.000 premi di azioni restritte che si vestono secondo obiettivi di crescita delle vendite nette per gli esercizi chiusi al 31/12/22 fino al 31/12/25.

KORU Medical Systems (KRMD) informó de una transacción de insider de acciones. El 16/10/2025, la Presidenta y CEO recibió 29.463 acciones comunes a un precio de 4,08 USD por acción según su acuerdo de empleo, como la parte en acciones del bono anual 2024 (30% acciones, 70% en efectivo).

Tras la operación, ella poseía beneficiariamente 1.052.626 acciones. Esto incluye 200.000 premios de acciones restringidas que se consolidan de acuerdo con un calendario de capitalización de mercado antes del 15/03/27, y 600.000 premios de acciones restringidas que se consolidan según metas de crecimiento de ventas netas para los ejercicios fiscales terminados el 31/12/22 hasta el 31/12/25.

KORU Medical Systems (KRMD)는 내부자 주식 거래를 보고했습니다. 2025년 10월 16일, 사장 겸 CEO는 고용 계약에 따라 2024년 연간 보너스의 주식 부분(주식 30%, 현금 70%)으로 주당 4.08달러의 일반주 29,463주를 받았습니다.

거래 후 그녀는 유익하게 1,052,626주를 소유하게 되었습니다. 여기에는 200,000주 제한 주식 보상이 포함되며 이는 2027년 3월 15일 이전의 시장자본화 일정에 따라 귀속되고, 600,000주 제한 주식 보상은 2022년 12월 31일부터 2025년 12월 31일까지의 순매출 성장 목표를 기반으로 귀속됩니다.

KORU Medical Systems (KRMD) a publié une opération sur actions par initié. Le 16/10/2025, la Présidente et PDG a reçu 29 463 actions ordinaires à 4,08 USD par action dans le cadre de son accord d'emploi, en tant que la partie actions du bonus annuel 2024 (30% actions, 70% en espèces).

Après la transaction, elle détenait bénéficiairement 1 052 626 actions. Cela comprend 200 000 attributions d'actions restreintes qui vestent selon un calendrier de capitalisation boursière avant le 15/03/27, et 600 000 attributions d'actions restreintes qui vestent selon des objectifs de croissance du chiffre d'affaires net pour les exercices clos au 31/12/22 au 31/12/25.

KORU Medical Systems (KRMD) meldete eine Insider-Eigenkapitaltransaktion. Am 16.10.2025 erhielt die Präsidentin und CEO im Rahmen ihrer Beschäftigungsvereinbarung als Aktienanteil des Jahresbonus 2024 (30% Aktien, 70% Bargeld) 29.463 Stammaktien zu 4,08 USD pro Aktie.

Nach der Transaktion besaß sie beneficial 1.052.626 Aktien. Dazu gehören 200.000 Restricted-Stock Awards, die gemäß einem Kalender zur Marktkapitalisierung vor dem 15.03.2027 vesten, sowie 600.000 Restricted-Stock Awards, die basierend auf Zielen zum Nettoumsatzwachstum für die Geschäftsjahre endend am 31.12.22 bis zum 31.12.25 vesten.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Tharby Linda M

(Last) (First) (Middle)
C/O KORU MEDICAL SYSTEMS, INC.
100 CORPORATE DRIVE

(Street)
MAHWAH NJ 07430

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
KORU Medical Systems, Inc. [ KRMD ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
President and CEO
3. Date of Earliest Transaction (Month/Day/Year)
10/16/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/16/2025 A 29,463(1) A $4.08 1,052,626(2) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. 29,463 shares issued per her employment agreement for 2024 annual bonus earned, of which 70% was paid in cash and 30% paid in shares of common stock.
2. Includes 200,000 in restricted stock awards that vest based on a schedule of the Company's market capitalization prior to 3/15/27; Includes 600,000 in restricted stock awards that vest based on a schedule of the Company's net sales growth targets for each of the fiscal years ended 12/31/22 through 12/31/25.
Remarks:
The filing of this statement shall not be construed as an admission (a) that the person filing this statement is, for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the beneficial owner of any equity securities covered by this statement, or (b) that this statement is legally required to be filed by such person. Power of Attorney has been previously filed.
/s/ Thomas Adams - Attorney-in-Fact 10/20/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did KRMD's CEO acquire according to the Form 4?

On 10/16/2025, the President and CEO received 29,463 shares of common stock at $4.08 per share as part of her 2024 annual bonus.

How many KRMD shares does the CEO beneficially own after the transaction?

She beneficially owns 1,052,626 shares following the reported transaction.

What portion of the 2024 bonus was paid in stock for KRMD's CEO?

30% of the 2024 annual bonus was paid in shares of common stock, with 70% paid in cash.

What restricted stock awards are included in the CEO's holdings at KRMD?

Holdings include 200,000 RSAs vesting on a market capitalization schedule prior to 3/15/27 and 600,000 RSAs vesting on net sales growth targets for fiscal years ended 12/31/22–12/31/25.

What was the transaction code for the KRMD CEO's share issuance?

The transaction was reported as an A code, indicating shares acquired.

Is the filing made by one or multiple reporting persons at KRMD?

It was filed by one reporting person.
Koru Med Sys

NASDAQ:KRMD

KRMD Rankings

KRMD Latest News

KRMD Latest SEC Filings

KRMD Stock Data

191.41M
42.38M
8.29%
55.73%
2.53%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States
MAHWAH